Relative risk confusion, the FDA weighs in on tweets, and what’s the right care with a new, expensive drug?
June 19, 2014
The FDA rules that drug companies must include both risks and benefits in tweets… Relative risk reduction is still misleading… An open letter on statins… What’s the right care with a new, expensive, drug like sofosbuvir? … Saying goodbye to Dr. Bud Relman…Read More